Original Article
Factors Associated with Emergency Department Visits in Asthma Exacerbation
Abstract
Objectives: Despite quality improvement initiatives to prevent asthma-related emergency department (ED) visits, rates have not declined. We sought to determine factors associated with ED visits in an underserved population.Methods: We performed a case–control analysis of asthma patients at three ambulatory care centers serving low-income populations. Cases consisted of asthmatic patients aged 18 to 45 years with ≥1 ED visit for an asthma exacerbation between August 1, 2008 and July 31, 2010. Controls were patients with asthma aged 18 to 45 years with ≥1 outpatient visit during the same period but with no asthma-related ED visit. Data were collected by chart review and included demographics, past referral for asthma education or to a pulmonologist, recent tobacco use, influenza vaccination, and asthma medication prescriptions in the year before the index visit.
Results: Among 244 cases and 475 controls, there were no significant differences in age, sex, or ethnicity. Cases were more likely than controls to have ever been referred for asthma education (odds ratio [OR] 4.09, 95% confidence interval [CI] 2.57–6.50) or to a pulmonologist (OR 2.31, 95% CI 1.15–4.66). In the year before the index visit, cases were more likely than controls to receive other medications in addition to inhaled corticosteroids (ICS; OR 1.74, 95% CI 1.14–2.66) but less likely to receive influenza vaccination (OR 0.49, 95% CI 0.34–0.71), a short-acting β-agonist (OR 0.43, 95% CI 0.24–0.78), or ICS alone (OR 0.53, 95% CI 0.34–0.84).
Conclusions: Markers of severe disease were associated with ED visits, as well as a lack of an influenza vaccination and failure to prescribe either ICS or short-acting β-agonists.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. National Heart, Lung, and Blood Institute, National Institutes of Health. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Publication No. 07-4051. Bethesda, MD: National Institutes of Health; 2007.
2. Jackson DJ, Sykes A, Mallia P, et al. Asthma exacerbations: origin, effect and prevention. J Allergy Clin Immunol 2011;128:1165-1174.
3. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. National Center for Health Statistics Brief Data. http://www.cdc.gov/nchs/data/databriefs/db94.pdf. Accessed December 14, 2012.
4. Szefler SJ. Advancing asthma care: the glass is only half full! J Allergy Clin Immunol 2011;128:485-494.
5. Eisner MD, Katz PP, Yelin EH, et al. Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity. Respir Res 2001;2:53-60.
6. Boudreaux ED, Emond SD, Clark S, et al. Acute asthma care among adults presenting to the emergency department: the role of race/ethnicity and socioeconomic status. Chest 2003;124:803-812.
7. Lang DM, Polansky M, Sherman MS. Hospitalizations for asthma in an urban population: 1995Y1999. Ann Allergy Asthma Immunol 2009;103:128-133.
8. Markovitz BP, Andresen EM. Lack of insurance coverage and urgent care use for asthma: a retrospective cohort study. BMC Public Health 2006;6:14.
9. Montana Department of Public Health and Human Services. Asthma surveillance report October-December 2011. http://dphhs.mt.gov/Portals/85/publichealth/documents/Asthma/SurveillancereportOctDec2011.pdf. Accessed December 14, 2012.
10. Environmental Protection Agency US. Asthma Facts. http://www.epa.gov/asthma/pdfs/asthma_fact_sheet_en.pdf. Published March 2013. Accessed January 27, 2015.
11. Hosmer DW, Lemeshow S. Applied Logistic Regression, Second Edition. New York: John Wiley and Sons, 2000.
12. National Committee for Quality Assurance. Quality of care measurement: asthma, 2008. http://www.ncqa.org/Portals/0/Newsroom/SOHC/SOHC_08.pdf. Accessed December 14, 2012.
13. Smith K, Warholak T, Armstrong E, et al. Evaluation of risk factors and health outcomes among persons with asthma. J Asthma 2009;46:234-237.
14. Hasegawa K, Tsugawa Y, Brown DF, et al. A population-based study of adults who frequently visit the emergency department for acute asthma. California and Florida, 2009-2010. Ann Am Thor Soc 2014;11:158-166.
15. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008;32:545-554.
16. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med 2013;8:639-652.
17. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone while it improves asthma control and quality of life. Am J Resp Crit Care Med 1995;152(5 Pt 1):1467-1473.
18. Harrison TW, Oborne J, Newton S, et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363:271-275.
19. Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2005;4:CD003135.
20. Sin DD, Man SF. Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma. Arch Intern Med 2002;162:1591-1595.
21. National Heart, Lung, and Blood Institute. Inhaled corticosteroids: keep airways open. http://www.nhlbi.nih.gov/health/prof/lung/asthma/naci/discover/corticosteriods.htm. Accessed December 14, 2012.
22. Hasegawa K, Brenner BE, Clark S, et al. Emergency department visits for acute asthma by adults who ran out of their inhaled medications. Allergy Asthma Proc 2014;35:42-50.
23. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011;364:1695-1707.
24. Kaplan S, Zhou EH, Iyasu S. Characterization of long-acting beta2-adrenergic agonists utilization in asthma patients. J Asthma 2012;49:1079-1085.
25. Centers for Disease Control and Prevention. Seasonal influenza vaccine safety: a summary for clinicians. http://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm. Accessed April 8, 2012.
26. Kmiecik T, Arnoux S, Kobryn A, et al. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine. J Asthma 2007;44:817-822.
27. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001;345:1529-1536.
28. Teichtahl H, Buckmaster N, Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest 1997;112:591-596.
29. Centers for Disease Control and Prevention. Influenza vaccination: a summary for clinicians. http://www.cdc.gov/flu/professionals/vaccination/vax-summary.htm. Accessed March 29, 2015.
30. Misky GJ, Wald HL, Coleman EA. Post-hospitalization transitions: examining the effects of primary care provider follow-up. J Hosp Med 2010;5:392-397.
31. Stankiewicz-Choroszucha BL, Wawrzyniak ZM, Lipiec A, et al. Consequences of smoke inhalation in the ‘‘Epidemiology of Allergic Diseases in Poland’’ project (ECAP). Ann Agric Environ Med 2011;18:420-428.
32. Laurendi G, Mele S, Centanni S, et al. Global alliance against chronic respiratory diseases in Italy (GARD-Italy): strategy and activities. Respir Med 2012;106:1-8.
33. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest 2006;130(1 suppl):65S-72S.
